RBC Capital Upgrades Sarepta Therapeutics to Outperform, Announces $182 Price Target
Portfolio Pulse from Benzinga Newsdesk
RBC Capital has upgraded Sarepta Therapeutics (NASDAQ:SRPT) from Sector Perform to Outperform, with a new price target of $182.
July 29, 2024 | 10:40 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
RBC Capital has upgraded Sarepta Therapeutics from Sector Perform to Outperform, setting a new price target of $182. This upgrade is likely to positively impact the stock price in the short term.
Analyst upgrades, especially from reputable firms like RBC Capital, often lead to positive short-term price movements. The new price target of $182 suggests significant upside potential.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100